Novome Biotechnologies

Novome Biotechnologies is a clinical stage biotechnology company developing engineered cellular therapies for the gut to treat chronic diseases. Novome has developed the first platform for the controlled colonization of the gut with engineered bacteria to deliver targeted therapeutic cargos and functions, enabling first-in-class living therapeutics: Genetically Engineered Microbial Medicines (GEMMs). Our lead program in enteric hyperoxaluria is in Ph 2, which is focused on the development of a therapeutic strain of bacteria that degrades oxalate to decrease the risk of kidney stone formation. Efforts are also directed toward advancing pipeline indications pipeline indications in inflammatory bowel disease, where we have a multi-target collaboration with Genentech, irritable bowel syndrome and immuno-oncology. Novome is backed by leading investors, including 5AM Ventures, Alta Partners and DCVC Bio.